SAM
PRTK

Sectoral Asset Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Sectoral Asset Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-12,739
Closed -$124K – 144
2018
Q3 		$124K Buy
+12,739
New +$128K 0.01% 153

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
APCM
Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Sectoral Asset Management's PRTK Position: Q4 2018 in Review

Sectoral Asset Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2018, closing a stake of 12,739 shares — an estimated $124K sold.

Sectoral Asset Management first reported a position in PRTK in Q3 2018 and held it in 1 quarter. The position peaked at $124K in Q3 2018. 102 funds tracked by Wall St. Rank hold PRTK as of Q4 2018.

  • Sectoral Asset Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Sectoral Asset Management sold 12,739 Paratek Pharmaceuticals, Inc. shares in Q4 2018, an estimated $124K.
  • Sectoral Asset Management first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2018 and held it in 1 quarter.
  • Sectoral Asset Management's Paratek Pharmaceuticals, Inc. position peaked at $124K in Q3 2018.
  • 102 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2018.

Based on Sectoral Asset Management's 13F filing for Q4 2018, filed 12 Feb 2019.